Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

Dr. Jay Bhattacharya told Sen. Josh Hawley that he supports developing alternatives for vaccines and therapeutics that use aborted cell lines.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

Indigenous peoples and local communities scored perhaps the most tangible progress as the 16th United Nations, or COP16 ...

-- A German court in Duesseldorf ruled that Pfizer and partner BioNTech broke a coronavirus vaccine patent held by Moderna, Reuters reports. -- The court said Pfizer and BioNTech would have to provide ...